Elevance Health (NYSE:ELV) Price Target Raised to $363.00 at Deutsche Bank Aktiengesellschaft

Elevance Health (NYSE:ELV) had its price target increased by Deutsche Bank Aktiengesellschaft from $332.00 to $363.00 in a report published on Thursday morning,MarketScreener reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

Several other equities analysts have also recently weighed in on ELV. Sanford C. Bernstein raised their target price on shares of Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research note on Friday. Barclays reissued an “overweight” rating and issued a $408.00 target price on shares of Elevance Health in a research note on Friday. The Goldman Sachs Group raised their target price on shares of Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday. Robert W. Baird raised their target price on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $384.65.

Elevance Health Stock Up 0.0%

Shares of ELV traded up $0.07 during mid-day trading on Thursday, hitting $346.36. 242,114 shares of the company’s stock were exchanged, compared to its average volume of 1,858,477. The company has a market cap of $76.08 billion, a PE ratio of 14.73, a P/E/G ratio of 1.83 and a beta of 0.49. Elevance Health has a 52 week low of $273.71 and a 52 week high of $427.54. The company has a 50-day simple moving average of $309.00 and a 200 day simple moving average of $331.66. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts forecast that Elevance Health will post 25.5 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is presently 27.39%.

Institutional Investors Weigh In On Elevance Health

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Elevance Health by 0.6% in the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares in the last quarter. Wellington Management Group LLP raised its stake in Elevance Health by 25.2% in the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock valued at $2,906,051,000 after purchasing an additional 1,668,679 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Elevance Health by 27.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after purchasing an additional 1,607,274 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in Elevance Health by 10.0% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,032,751 shares of the company’s stock valued at $1,764,231,000 after purchasing an additional 455,946 shares in the last quarter. Finally, First Eagle Investment Management LLC raised its stake in Elevance Health by 0.6% in the fourth quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after purchasing an additional 24,271 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results and guidance lift sentiment — ELV reported better-than-expected Q1 EPS and raised its 2026 adjusted EPS outlook (targets 12% EPS growth in 2027), signaling stronger profitability and upward earnings momentum. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Management cites medical-cost controls and AI-driven operating discipline as drivers of margin expansion and a higher annual profit forecast — supports sustainable margin improvement. Health insurer Elevance raises annual profit forecast
• Positive Sentiment: Investment income helped EPS — rising net investment income materially boosted Q1 results, offsetting some membership pressure. ELV Beats Q1 on rising net investment income
• Positive Sentiment: Analyst support: Evercore raised its price target to $360, adding buy-side validation for the beat-and-raise story. Evercore raises price target on Elevance
• Positive Sentiment: Shareholder return: Board declared a quarterly dividend (supports income-oriented investors and reduces downside risk).
• Neutral Sentiment: Analyst stance mixed — Robert W. Baird raised its target to $331 but moved to a “neutral” rating, reflecting more cautious near-term expectations despite higher valuation work. Baird updates target and rating
• Neutral Sentiment: Operational caveat: Management noted membership declines; the topline impact is being offset by investment income and cost controls — watch membership trends for sustainability. Valuation and mixed Q1 draw attention
• Negative Sentiment: Legal risk: A law firm (Kirby McInerney LLP) has launched an investor investigation into potential securities-law claims involving Elevance and senior management — introduces regulatory/legal overhang and potential litigation risk. Investor alert: Kirby McInerney investigates Elevance

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.